# A Clinical Study to Evaluate the Safety, Tolerability and Activity of a New Phosphate Binder (SBR759) in Patients With Chronic Kidney Disease on Hemodialysis

> **NCT00750295** · PHASE1,PHASE2 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 60 (actual)

## Conditions studied

- Chronic Kidney Disease

## Interventions

- **DRUG:** SBR759
- **DRUG:** SBR759
- **DRUG:** SBR759
- **DRUG:** SBR759
- **DRUG:** SBR759
- **DRUG:** SBR759
- **DRUG:** SBR759

## Key facts

- **NCT ID:** NCT00750295
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-02
- **Primary completion:** 2008-01
- **Final completion:** 2008-01
- **Target enrollment:** 60 (ACTUAL)
- **Last updated:** 2020-12-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00750295

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00750295, "A Clinical Study to Evaluate the Safety, Tolerability and Activity of a New Phosphate Binder (SBR759) in Patients With Chronic Kidney Disease on Hemodialysis". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT00750295. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*